RAS Blockade Discontinuation Tied With Death, MACE in Advanced Kidney Disease
Study findings suggest the benefits of continuing ACEi or ARB therapy outweigh the risks in CKD patients with an eGFR less than 30 mL/min/1.73 m2.
Hyperkalemia
HYPERKALEMIA
Managing Electrolyte Imbalances in Kidney Transplant Recipients
Hyperkalemia, hypomagnesemia, and hyperparathyroidism commonly persist after kidney transplant surgery.
Potassium Binder Found Effective Regardless of CKD Stage
In a study, sodium zirconium cyclosilicatesimilarly maintained normokalemia in nondialysis CKD patients with an eGFR above and below a threshold of 30 mL/min/1.73 m2.
Inappropriate Prescribing May Up Hyperkalemia Risk in Elderly CKD Patients
Polypharmacy and medication errors can expose elderly patients with chronic kidney disease to an increased risk of hyperkalemia and other problems, investigators reported.
Binder Safely Improves Hyperkalemia in Transplant Recipients
In a small study, use of the potassium binder sodium zirconium cyclosilicate in transplant recipient did not appear to compromise immunosuppression with tacrolimus.
Patiromer Being Used for Chronic Hyperkalemia Management
Findings from a real-world study of veterans revealed persistent use of patiromer in many patients over a 6-month period following initiation of the drug.
Transforming Renal Care for Patients with Hyperkalemia
Content sponsored by AstraZeneca An estimated 37 million Americans in the United States (US) live with chronic kidney disease (CKD) and its complications. That’s roughly 15 percent of the adult population.1 Despite the high unmet need, innovation has lagged in comparison to other disease areas. It’s time for that dynamic to change. Health care providers…
Potassium Abnormalities Up 1-Year Mortality in Hospitalized Patients
In a study of hospitalized patients, hypokalemia and hyperkalemia at admission were associated with an increased 1-year mortality risk.
SZC Corrects, Maintains Potassium in Diverse Populations
Sodium zirconium cyclosilicate produced dose-dependent reductions in serum potassium in an international cohort of hyperkalemic outpatients.
Dyskalemia at ICU Admission Ups Cardiac Event, Death Risks
Failure to correct dyskalemia within 2 days increased 28-day mortality risk.
Want to read more?
Please login or register first to view this content.
Next post in Hyperkalemia
